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Introduction 
Cystic fibrosis is a genetically inherited disease that occurs in one out of every 2000 live, 
caucasian births, and is the most common lethal, genetic disease of Caucasians.1 The inheritance of 
this disease appears to follow an autosomal recessive pattern, and approximately five percent of 
Amer icans are asymptomatic carriers of the cystic fibrosis gene. The majority of cystic fibrosis 
patients present with a triad of characteristic signs: obstructive pulmonary disease, pancreatic 
achylia, and increased sweat sodium chloride concentration. Pulmonary complications have 
accounted for 8S much as 90& of the mortality associated with cystic fibrosis,' and recurrent 
pulmonary infections requiring hospitalization continue to be the major cause of the morbidity, 
mortality, and expense that these patients and their families suffer. 
Pulmonary infections in cystic fibrosis patients are often caused by Staphylococcus 
aureus  early in the disease, but as the disease progresses over time, most patients eventually 
become infected and/or colonized with Pseudomonas  aeruginosa,'  a gram-negative 
microorganism with a known propensity for antimicrobial resistance. Pseudomonas 
aeruginosa  is also a major pathogen in other patient populations such as patients with 
malignancy, burn and trauma patients, and otherwise immunocompromised hosts, but cystic 
fibrosis patients have a much higher prevalence of Pseudomonas  aeruginosa  infection, as high 
8s 7 0 & . 2 The pathogenicity of this organism has been recognized for many years,3 and resistance 
to antibiotics via B-lactamase production and other mechanisms has long been a problem. The 
virulence of Pseudomonas  aeruginosa  has been attr ibuted to both direct tissue damage by 
bacterially produced toxins and enzymes (e.g., exotoxin A , cytotoxin, exoenzyme S, protease, 
elastase, and phospholipase C), and to activation of specific (antibody and complement) and 
nonspecific (inflammation) host immune responses.4-5 In addition, antibody to Pseudomonas 
aeruginosa  exotoxin A has been demonstrated in the serum of patients with cystic fibrosis,4 
further evidence of the role of this organism in the pathogenesis of this disease. 
•p 
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An unusual aspect of pulmonary Infections in cystic fibrosis patients is the high rate of 
mucoid strains of Pseudomonas  aeruginosa  isolated from the sputum, a finding not commonly 
encountered in other patient populations. There are several characteristics of these strains that 
may contribute to the unusually high rate of relapse seen following intensive antibiotic therapy. 
These mucoid strains produce slime that encloses large masses of bacteria which may add to airway 
dysfunction and atelectasis, and may result in resistance to phagocytosis and decreased penetration 
of antibodies and antibiotics.4 These mucoid strains also have been reported to have an increased 
intrinsic resistance to antibiotics in  v/(ro,A  although Parry and collegues6 published conflicting 
data. 
Current approaches to treatment of Pseudomonas  aeruginosa  pneumonia in cystic 
fibrosis patients usually include intensive pulmonary toilet, nutritional support, and drug 
therapy using a combination of fi-lactam and aminoglycoside antibiotics. Although this approach 
has been adopted by the majority of cystic fibrosis treatment centers, it remains controversial in 
light of reports which have shown conflicting results from therapy using agents with activity 
against Pseudomonas  species versus treatment regimens without antipseudomonal 
a g e n t s , 7 ' 8 ' 9 - 1 0 However, in spite of data that challenge the need for antipseudomonal therapy, 
most clinicians continue to treat pulmonary exacerbations in cystic fibrosis patients with 
aggressive antimicrobial chemotherapy. In addition to the continuing problem of resistance of 
Pseudomonas  aeruginosa  to antibiotics, the toxicity of the am inoglycosides to the renal, 
cochlear, and vestibular systems Is also a major concern. Clearly, the need for safer and more 
effective antipseudomonal agents exists. Currently, the agents with the greatest activity against 
Pseudomonas  aeruginosa  are piperacillin, azloctllin, ceftazidime, cefsulodin, cefoperazone, 
amikacin, tobramycin, Imipenem, and aztreonam.5 
Aztreonam is the first of a new class of fl-lactam antibiotics called the monobactams. The 
monobactam antibiotics differ from other B-lactam antibiotics in that they are completely 
synthetic In origin, and the B-lactam ring is not fused to another ring system as In the penicillins 
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and cephalosporins (see Figure). Hence, these molecules are monocyclic 6-lactams, from which 
the name rnonobactam was derived. Aztreonam also differs from other J3~laetam antibiotics in its 
spectrum of activity by being active almost exclusively against gram-negative aerobic bacteria. 
The mechanism of action of aztreonam is very similar to the other lactam antibiotics; it binds to 
penicillin binding proteins (PBP's) to inhibit bacterial cell wall synthesis. Aztreonam binds to 
PBP 3, inhibiting the ability of bacterial cell wall to septate during cell division, resulting in long 
filamentous cells and eventually cell death. The spectrum of activity of aztreonam Includes most 
Enterobacieriaceae,  Neisseria  species, and Haemophilus  species, and it has significant 
activity (minimum inhibitory concentration of 905& of organisms [MIC90] < 16 meg/ml) against 
Pseudomonas  aeruginosa,  Enterobacter  species, and Serratia  marcescens.^ 
Aztreonam has been investigated in the treatment of a variety of infections, Including infections of 
the urinary tract, bacteremia, skin and deep soft tissue, chronic osteomyelitis, septic arthritis, 
abscesses, pneumonia, postpartum endometritis, and intraabdominal infections.' 1.12,13 
Aztreonam has been effective in the treatment of gram-negative infections as single-agent 
therapy,1 1 In phase I, II and early phase III trials, aztreonam has shown little or no potential for 
renal toxicity and appears to cause less diarrhea than conventional therapy due to less alteration of 
normal gut f l o r a . 1 3 Adverse reactions, like other 13-lactam antibiotics, have been minimal in 
clinical trials to date. In multiple-dose studies, aztreonam has shown a number of effects, 
including local reactions such as phlebitis or swelling in 2.4 percent of patients treated, rash 
and/or pruritis in 1.6 percent, nausea and/or vomiting in 0.9 percent, and diarrhea in 0.8 
percent of patients,12 Transient elevations in liver enzymes also have been reported, although 
inconsistently.1 1 '1 2 Enterococcal superinfection has been reported following treatment with 
aztreonam.14 Following intravenous administration, aztreonam exhibits first-order elimination 
kinetics with an elimination half-life of approximately 1 , 7 hours. The drug is 56 percent bound 
to serum proteins, and 60 to 7 0 percent of a dose is renally excreted.15 
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Purpose, The purpose of this study was to examine the efficacy of aztreonam in the 
treatment of gram-negative pneumonia In patients with cystic fibrosis, Aztreonam has been 
shown in preliminary studies to be effective in the treatment of Pseudomonas  aeruginosa 
infections, A more effective antipseudomonal agent may help increase the life expectancy of cystic 
fibrosis patients, as well as help control the high health care costs these patients incur. 
Materials and Methods 
This study design was open-label with no controls. The study received Institutional 
Review Board approval prior to enrolling any patients. Participants in this study were 
consecutively selected from cystic fibrosis patients admitted to the pediatrics unit at University 
Hospital, Salt Lake City, Utah, for parenteral antibiotic treatment of pulmonary exacerbation of 
cystic fibrosis. Informed written consent (Appendix B) was obtained for all patients prior to 
beginning the study either from the patients ( 1 8 years of age or older), or their legal guardians. 
For those cases in which the patient was considered a competent minor ( i 2 years of age or older), 
written assent from the patient was also obtained, inclusion criteria were as follows: 
1. Six years of age or older 
2. Documented gram-negative pulmonary Infection by sputum culture 
3. Documented sensitivity of the infecting organism to aztreonam 
4. No history of anaphylactic (type 1) reaction to penicillins 
5. Non-lactating or non-pregnant females 
6. No evidence of severe hepatic dysfunction as Judged by: 
-aspartate aminotransferase (AST) or alanine aminotransferase ( A L T ) greater 
than three times the upper limit of normal 
-total serum bilirubin greater than 1.5 times the upper limit of normal 
7. No concurrent severe disease, such as neoplasm, that may limit survival during the 
study period 
8. No granulocytopenia (absolute neutrophil count less than 1 0 O O ) or other significant 
immunodeficiency 
9. Serum creatinine level less than the upper limit of normal for age and weight per 
University Hospital standard, and no other evidence of renal dysfunction 
10. No evidence of heart failure 
11. No other condition making the patient unsuitable for enrollment in the study 
Initial assessment. All patients received an initial assessment on admission to the 
study which consisted of a complete history and physical examination, chest roentgenogram, 
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complete blood count with white cell differential, 20-channel blood analysis (including; sodium, 
potassium, cnionae, Dicaroonate, creatinine, mooa urea nitrogen, glucose, calcium, phosphate, 
uricacid, AST, A L T , gamma-glutamyl transpeptidase, lactic dehydrogenase, alkaline phophatase, 
creatine kinase, total protein, albumin, and direct and total bilirubin), urinalysis, and sputum 
sample (obtained before starting antibiotic therapy) for quantitative microbiology and sensitivity 
testing, A complete blood count with white cell differential, 20-channel blood analysis, 
urinalysis, and sputum culture and sensitivity were repeated every five days during therapy and 
on the last day of therapy, and sputum culture and sensitivity again at the follow up assessment 7 
to 14 days after cessation of therapy. 
Processing of sputum samples. Sputum samples obtained before therapy was 
started, every five days during therapy, on the last day of therapy, and at the follow up visit were 
each subjected to the same process. Acceptable samples were defined as having fewer than ten 
epithelial cells per low power ( 1 0 O x ) field and more than 2 5 whits blood tails per low power 
field. First , sputum was diluted into three tubes containing tryptic soy broth (TSB) to 
concentrations of 0.01 ml sputum per 0,1 ml of TSB ( 1 : 1 0 dilution), 0.01 ml sputum per 1 ml of 
TSB ( 1 : 1 0 0 dilution), and 0.001 ml sputum per 1 ml of TSB ( 1 : 1 0 0 0 dilution). Then, from the 
undiluted sputum and each of these dilutions, 0 . 0 1 ml arid 0,001 ml volumes were plated out on 
blood, chocolate, 8nd MacConkey agar plates, representing volumes of 0 . 0 1 , 0 . 0 0 1 , 0 . 0 0 0 1 , and 
0.00001 ml of undiluted sputum onto these agar media, These plates were incubated for 2 4 - 4 8 
hours at 35°C, at which time the colonies were counted. Colony counts were expressed as colony 
forming units ( C F U ) per milliliter. Individual colonies were then taken, isolated for pure 
culture, and identified. These isolates were placed in broth and incubated another 24 hours, The 
broth was then standardized to 0.5 MacFarland standard (representing 5x 1 0 8 CFU per ml for 
Pseudomonas  aeruginosa)  and smeared on a Kirby-Bauer disk-diffusion plate onto which 
disks containing standard concentrations of the following antibiotics were placed for sensitivity 
testing: aztreonam,tobramycin,gentamicin,cefoperazone, moxalactam, piperacillin,and 
amikacin. The isolates were also placed on serial dilution agar plates for MIC testing. Agar 
dilution and Klrby-Bauer plates were read after another 24 hours of Incubation. Aztreonam 
sensitivity was defined as a disk diffusion zone size equal to or greater than 21 mm, and MIC i 8 
mcg/ml. Intermediate sensitivity was defined as a zone size equal to or greater than 16 mm but 
less than 21 mm, and MIC = 16 mcg/ml. Organisms with zone sizes less than 16 mm, and MIC i 
32 mcg/ml, were defined as resistant to aztreonam. 
Scoring. The numerical scoring system of Beaudry, et a l , 1 0 was used to assess the 
severity of the patients' pulmonary disease. This assessment was done on the first day of therapy, 
repeated every seven days during therapy, and again at the follow up visit. The scale consisted of 
zero to three points, based on severity (zero being no symptom and three being severe symptom), 
for each of the following areas: cough, sputum production, cyanosis, retractions on inspiration, 
temperature, heart rate, and respiratory rate (Appendix C). Patient progress was also assessed 
daily by recording vital signs (temperature, blood pressure, heart rate, and respiratory rate) 
every eight hours and using a second scoring system in which the patient's status was quantified 
using a scale from one to four, with one being no symptom and four being severe symptom, in each 
of the following areas: cough, rales/rhonchi, chills, consolidation/pleural effusion, decreased 
pulmonary function, and symptoms related to bronchitis (Appendix D), 
Dosing. Following initial assessment and collection of laboratory specimens, all patients 
received aztreonam, 50 mg/kg IV every six hours (supplied by E.R. Squibb & Sons, Inc., 
Princeton, N J ) . The drug was reconstituted and diluted to a concentration of less than 2 mg per 
100 ml of diluent. Using a constant rate syringe pump (Harvard M1ni-lnfuser 100, C.R, Bard, 
Inc., North Reading, MA) drug was Infused over approximately 30 minutes. For patients In whom 
gram-positive organisms were documented or strongly suspected (recent previous Infection with 
documented gram-positive infection), an agent with the appropriate antibacterial spectrum, but 
without gram-negative activity, could be started in appropriate doses. All patients received chest 
HH8SBIHP 
percussion and postural drainage five times per day, nutritional support, and oxygen and/or 
oroncnoanaior tnerapy wnen neeaea. patients were not anowea to taxe any antioiotics during tne 
period between the last day of therapy and the follow up visit. 
Following completion of the study, all patients were assessed as to their clinical and 
microbiological response, according to the following definitions: 
Microbiological Response 
Cure; Causative organism(s) eliminated or at least one-log decrease in sputum 
colony count on the last day of treatment or, if no culture done at that time, 
within two days of the last treatment day. 
Cure with relapse: Causative organism(s) eliminated or at least one-leg decrease 
in sputum colony count at the end of treatment but recurrence of infection due to 
an organism of the same species during the follow up period. 
Cure with reinfection: Causative organlsm(s) eliminated or at least one-log 
decrease in sputum colony count at the end of treatment but recurrence of 
Infection due to a different organism during the follow up period. 
Failure: Persistence (less than one-log decrease, no change, or increase in 
sputum colony counts) of causative organism(s) at end of treatment. 
Superinfection: Occurrence of infection (as evidenced by clinical signs and 
symptoms of Infection and requiring therapy) at the same site due to different 
pathogen(s) during aztreonam therapy. 
Treatment emergent: Isolation of new nonpathogenic isolate(s) at the same site 
during treatment. 
Subsequent infection: Emergence during treatment or at follow up of an infection 
at a different site. 
Clinical Response 
Cure: Defervescence and complete resolution of signs and symptoms of lower 
respiratory tract Infection. 
Partial response: Substantial or temporary improvement in signs and symptoms 
of lower respiratory tract infection without complete resolution. 
Failure: Persistence or progression in signs or symptoms of infection. 
Statistical analysis. Data used for statistical analyses were white blood cell counts at 
entry into the study, at day five of therapy, and at the end of therapy, pulmonary status scores 3t 
fgt 
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entry, day seven, and follow up, dally clinical scores at entry, day five, end of therapy, and follow 
up, and colony counts of aztreonam-sensittve Isolates of Pseudomonas  aeruginosa  at entry, 
day five, end of therapy, and follow up. The data were analyzed using a one-way analysis of 
variance with repeated measures, and followed with Scheffe's test for determination of differences 
between groups. Statistical significance was defined as p less than or equal to 0.05. 
Results 
Of 25 patients entered into the study, 23 completed at least five days of therapy according 
to protocol and 20 had data collected at least at entry into the study, at five and seven days of 
therapy, at the and of therapy, and at the follow up visit, The duration of therapy ranged from 5 to 
19 days (mean = 1 1 . 5 days). Two patients were dropped from the study when they were found to 
be infected with gram-negative pathogenic organisms resistant to aztreonam. Data from the above 
20 patients were used for analysis. 
The patients ranged in age from 6 to 32 years (mean = 13.8); 14 were males and 11 were 
females. Demographics of all patients are presented in Table 1, With the exception of the two 
patients dropped from the study, all patients improved clinically during treatment with 
aztreonam. At least one strain of Pseudomonas  aeruginosa  was isolated from all patients, and 
in six patients Pseudomonas  cepacia  was found on sputum culture. Other gram-negative 
organisms isolated were Escherichia  coli  (two patients), Enterobacier  aggbmerans  (two 
patients), Enterobacier  cloacae  (two patients), Pseudomonas  fluorescens  (two 
patients), Haemophilus  influenzae  (two patients), and Klebsiella  oxytoca  (two patients). 
The mean values of the white blood cell counts, pulmonary status scores, daily clinical 
scores, and colony counts of Pseudomonas  aeruginosa  isolates are presented in Table 2. The 
white blood cell counts decreased from 1 0 . S ± 3 . 3 (mean±S.D.) on the first day of therapy to 
7 .4± 1 , 8 at the end of therapy with statistical significance (p<0.05), but the decreases from the 
first day to day five ( 8 . 6 * 2 . 6 ) , and from day five to the end of therapy did not achieve statistical 
significance (p>0.05). Pulmonary status score decreases between the first day of therapy 
( 6 . 3 ± 2 . 5 ) and day seven ( 2 . 5 ± 2 . 1 ) , and the first day of therapy and follow up ( 2 . 7 ± 2 . 2 ) were 
Dotn statistically significant, indicating improvement in pulmonary status. The pulmonary status 
scores increased slightly from day seven to follow up, but this change was not statistically 
significant. The daily clinical scores showed statistically significant decreases from the first day 
( 1 4 . 6 ± 3 . Q ) to day five ( 1 0 . 1 ± 2 . 4 ) , from the first day to the end of therapy ( 7 , 7 ± 1 , 7 ) , and from 
the first day to follow up ( 9 . 2 * 3 . 3 ) , also indicating improvement. Patients continued to improve 
after five days of therapy as shown by statistically significant improvement in clinical scores 
between day five and the end of therapy. Clinical scores increased between the end of therapy and 
follow up, and this change was also statistically significant, Indicating a worsening of clinical 
status after therapy was stopped. Perhaps of most Importance, the colony counts of susceptible 
Isolates of Pseudomonas  aeruginosa  showed a statistically significant decrease from 4.4±3.9 
l o g 1 0 on the first day of therapy to 1 ,2±2.3 l o g 1 0 at the end of therapy, but statistical significance 
was also achieved by the increase in colony counts from the end of therapy to follow up (4.4±3,9 
l o g 1 0 ) , indicating persistence of the original infection or possibly reinfection. (It is coincidental 
that the colony counts on the first day and at follow up are identical to one decimal point.) The 
mean MIC of isolated mucoid strains of Pseudomonas  aeruginosa  susceptible to aztreonam was 
8.5 mcg/ml, while that for the nonmucoid strains was 7 . 3 mcg/ml. Of the 33 isolated strains of 
Pseudomonas  aeruginosa  isolated on day one and/or day five of therapy and sensitive to 
aztreonam, 21 were eradicated by the last day of therapy, and ten of these continued to be 
eradicated at follow up. 
Of the 20 ©valuable patients, seven either had no sputum production (two) or had no 
growth on sputum culture (five) at the end of treatment. The two patients unable to produce 
sputum (patients 4 and 5) continued to be unable to produce a sputum sample at follow up, while 
one (patient 2 1 ) of the other five patients with sterile sputums at the end of treatment continued 
to have sterile sputum at follow up, and a second (patient 15) of these five patients was unable to 
produce sputum at follow up. 
1 0 
Emergence of resistance was defined as any isolate sensitive to aztreonam when first 
isolated which was shown to be resistant ( M I C i 32 mcg/ml) at subsequent culture and sensitivity 
testing. Of a total of 65 strains of Pseudomonas  aeruginosa  isolated during the study, three 
were resistant to aztreonam on initial sensitivity testing, and five were resistant at at least one 
subsequent sampling point after having been shown sensitive to aztreonam when first isolated. Of 
the six patients with resistant Pseudomonas  aeruginosa,  only one fa1 led to Improve clinically 
by the end of therapy. Other gram-negative organisms which were resistant to aztreonam on 
Initial sensitivity testing were three strains of Pseudomonas  cepacia  {patients  2 , 1 1 , and 
2 4 ) , two strains of Pseudomonas  species other than aeruginosa (patient 1 1 , the species could 
not be identified), and two strains of Pseudomonas  fiuorescens  (patients 11 and 12). 
Of the 20 evaluable cases in this study, six were determined, at completion of the study, to 
be clinical cures and 14 partial clinical responses. Microbiological cures were achieved in eight 
patients, cures with relapse in eight, cures with reinfection in two, and microbiological failures 
occurred In two patients. 
Discussion 
In this study, we found aztreonam to be effective in reducing the colony counts of most 
gram-negative organisms, including Pseudomonas  aeruginosa,  found in sputum cultures of the 
patients studied. In addition, patients improved clinically as manifested by decreased clinical and 
pulmonary status scores, and by decreased white blood cell counts during therapy. Clinical 
improvement continued beyond five days of treatment as shown by statistically significant 
decreases in clinical scores between day five of therapy and the last day of therapy, Pulmonary 
status scoring was not performed at the end of therapy, but this scale may also have shown further 
improvement between day seven and the end of therapy, since there was little change between day 
seven of therapy and follow up. We did not assess the correlation between microbiological 
response and clinical response, but other investigators have found clinical response to be 
independent of microbiological response,16 and Wientzen andcollegues7 and Nelson'7 have 
observed that Isolation of Pseudomonas  aeruginosa  or Staphylococcus  aureus  from the 
sputum of cystic fibrosis patients is as likely during asymptomatic intervals as during periods or 
pulmonary exacerbation. 
Although improvement during therapy occurred in this study, deterioration of patient 
status was seen between the last day of therapy and the follow up visit at 7 to 14 days 
posttreatment. Colony counts of Pseudomonas  aeruginosa  isolates had increased to 
pretreatment levels at the follow up visit, and clinical scores were statistically significantly 
increased over those obtained on the last day of therapy. Our inability to permanently and 
consistently eradicate Pseudomonas  aeruginosa  from the sputum, in spite of in  vitro 
susceptibility to the antibiotic used, is consistent with the experience of other 
investigators. 8 ' 1 0 - 1 6 > 1 8 Inhibitors of antibiotics in sputum have been identified and may help 
explain why these organisms persist in spite of in  vitro  susceptibility to antibiotics, but 
whether these inhibitors operate at the site of infection, the bronchial wall, is unknown.17 
Although 10 of 33 strains of Pseudomonas  aeruginosa  were eradicated at follow up in our 
study, the time of follow up was only 7 to 14 days following cessation of treatment, whereas most 
other investigators have evaluated patients one to six months after drug therapy has been stopped. 
The fact that our patients improved clinically despite the presence of Pseudomonas 
aeruginosa  in their sputa calls into question the importance of drug therapy directed at 
reducing or eradicating Pseudomonas  aeruginosa  from the sputum of cystic fibrosis patients. 
As suggested by Wientzen and collegues,7 the improvement in life expectant for cystic fibrosis 
patients may be due as much to intensive pulmonary toilet and attention to nutritional needs as to 
the use of antibiotics. Also, as mentioned above, Beaudry and collegues'0 have demonstrated no 
difference in clinical outcome between patients treated with carbenicillin plus gentamtcin and 
those who only received cloxacillin. Their patients Improved during hospitalization regardless of 
the antibiotic treatment received, However, these results are not supported by the studies of Hyatt 
and collegues,8 who found that patients had statistically significantly greater improvement after 
1 2 
treatment with oxacillin, sisomicin and carbenfclllin when compared to treatment with oxacillin 
alone, and Wientzen and collegues7 who found that their patients tended to do better when treated 
with tobramycin as opposed to placebo. 
The present stud/ does nothing to resolve the issue of whether or not to treat pulmonary 
exacerbation of cystic fibrosis with antipseudomonal agents since we did not include a treatment 
group who received no antipseudomonal agents, but it does show aztreonam to be a promising 
antipseudomonal agent should this eventually be shown to be the best approach. Aztreonam is at 
least as effective as other agents reported in the literature in reducing and eradicating 
Pseudomonas  aeruginosa  from the sputum of cystic fibrosis patients, and although our follow 
up period was only 7 to M days, the rate of eradication of Pseudomonas  aeruginosa  from 
sputum appears to exceed the rates found with most other antipseudomonal agents. However, this 
finding requires further verification after more Pseudomonas  infections have been exposed to 
aztreonam over time. 
Clinically, our patients continued to be improved at follow up compared to entry Into the 
stud/ as shown by statistically significant Improvement of follow up clinical scores and 
pulmonary status scores when compared to those done on the first day of treatment, and by the tack 
of a statistically significant increase (worsening) in pulmonary status scores between day 7 snd 
follow up. All 20 evaluable patients achieved at least partial clinical response during treatment 
with aztreonam, and all but two of these showed at least temporary microbiological cures, 
One area of difficulty In this study was the microbiologic tests performed, Emergence of 
resistance was difficult to identify due to the uncertainty that isolates found at one sampling time 
were in fact the same Isolates as those found at previous sampling times. This uncertainty arose 
from the variable morphology of Pseudomonas  aeruginosa  colonies found on the agar media 
and is demonstrated by the variable MIC's within a single Isolate (see Appendix A). The isolates of 
Pseudomonas  were also difficult to quantify, particularly the mucoid strains of Pseudomonas 
aeruginosa  , and speciation wasalso challenging at times. For example, patient 11 had three 
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strains of Pseudomonas  that could not be speciated using standard guidelines; they could only be 
Identified as non-aeruginosa. Krtlov and collegues19 had similar difficulties m identifying 
Pseudomonas  species, despite serotyplng, when they studied the efficacy of imlpenem 1n the 
treatment of pulmonary exacerbations of cystic fibrosis. The mucoid strains of Pseudomonas 
aeruginosa  are especially difficult to count and identify due to their dominance of the agar plate. 
Peir 2 stated that over 80$ of mucoid strains cannot even be serotyped. 
Emergence of resistance was not commonly found in our study. No patient experienced 
clinical deterioration as a result of the emergence of a resistant strain of Pseudomonas 
aeruginosa,  nor was any patient withdrawn from the study due to the Isolation of a resistant 
strain which was initially sensitive. Emergence of resistance of Pseudomonas  aeruginosa  to 
aztreonam has been reported, 2 0 - 2 1 although the number of rases to date have been few. However, 
emergence of resistance is an area of major concern in antimicrobial chemotherapy, especially 
with Pseudomonas  aeruginosa  While the addition of an aminoglycoside has reduced the rate of 
emergence of resistant strains of Pseudomonas  aeruginosa)^  this approach has not always 
been successful A 1 6 . 2 2 , n f a c t ( Sanders and Sanders 2 2 and Preheim and collegues^ have 
reported the emergence of strains of Pseudomonas  aeruginosa  and Enterobacter  aerogenes 
that have become resistant during therapy to both aminoglycosides as well as certain fi-laetam 
antibiotics (moxalactam, cefotaxime, ceftazidime, and cefsulodin). This resistance pattern cannot 
be explained by enzyme induction as described below. Preheim and collegues23 suggested that 
cross-resistance to aminoglycosides may be due to an alteration in the electron transport system 
resulting In diminished uptake of the aminoglycoside molecules. 
A major mechanism of resistance emergence is via the induction (or derepression) of a 
Rlchmond-Sykes type 113-lactamase enzyme. Emergence of resistant Pseudomonas 
aeruginosa  strains by this mechanism has been reported during treatment with moxalactam, 
cefotaxime, aztreonam, ceftizoxime, ceftriaxone, cefsulodin, and ceftazidime,22 agents which 
traditionally have had high activity against Pseudomonas  aeruginosa  Enzyme Induction 
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results m an overwhelming production of 0-lactamase which not only confers resistance to the 
original antibiotic agent, but also to the majority of other J3-lactam antibiotics, thereby rendering 
the organism resistant to virtually every available agent. This multiple resistant® is due to a 
trapping effect 1n which the antibiotic molecules are bound by the 13-lactamase molecules and, 
while they are not hydrolyzed, they are prevented from binding to their sites of action, the 
penicillin binding proteins. 2 2 - 2 4 An encouraging note Is that the new carbapenem, imlpenem, Is 
not affected by this type of resistance. The reason seems to be that imlpenem binds to penicillin 
binding protein 2 ( P B P 2 ) , and since there are far fewer P B P 2 sites than there are P B P 3 , for 
example, much less drug is needed to bind a sufficient number of target sites to inhibit cell wall 
synthesis.2 2 These data are tempered by the findings of Krtlov and collegues19 that showed a high 
rate of emergence of resistance to Imipenem therapy in cystic fibrosis patients with pulmonary 
exacerbation. I n their report, resistance was postulated to be due to ( 1 ) enzyme Induction or 
derepression, although they did point out that imipenem has not tended to be affected by this 
mechanism, ( 2 ) the structure of PBP2 being altered which reduced its affinity for imipenem, or 
( 3 ) the structure or function of the outer membrane porins of Pseudomonas  aeruginosa 
possibly being changed which would reduce the penetration of Imipenem Into the cell. The 
sensitivity patterns of these resistant isolates to other antimicrobial agents were not reported. 
Such Information may have helped Identify whether 13-lactamase Induction had occurred. 
The MIC's of the mucoid strains of Pseudomonas  aeruginosa  isolated from our study 
patients had a geometric mean of 2.1 mcg/ml, and that of the nonmucofd strains was 3.5 mcg/ml. 
This difference is slight, but appears to differ with the observation made by others that mucoid 
strains seem to have a higher Intrinsic resistance to antibiotics than nonmucoid strains.4 Similar 
to our findings, Parry and collegues6 reported that the strains of Pseudomonas  isolated from 
their cystic fibrosis patients fell Into one of two groups: ( 1 ) usually mucoid and highly sensitive 
to ticarcillin (MIC value * 1.6 ng/ml), and ( 2 ) usually nonmucoid with tlcarclllln MIC values of 
2 5 to 1 0 0 ug/ml. The Importance or even the existence of an Intrinsic resistance to antibiotic 
therapy of mucoid strains of Pseudomonas  aeruginosa  Is not clarified by the results of this 
study, Whether mucoid strains become yet another limiting factor In the treatment of 
Pseudomonas  pneumonia will require further research. 
An interesting finding in this study is the fact that although several strains of 
Pseudomonas  species other than aeruginosa (hereafter referred to as non-aeruginosa) were 
isolated from the sputum of some patients, these patients' courses seemed to be dependent on the 
aztreonam sensitivity pattern of the Pseudomonas  aeruginosa  isolates, regardless of the 
sensitivity patterns of the non-aeruginosa Pseudomonas.  One example 1s patient 11 who had 
four strains of non-aeruginosa Pseudomonas  in his sputum which were resistant to aztreonam, 
and two strains of Pseudomonas  aeruginosa  which were sensitive, and he showed partial 
clinical response and microbiological cure at the end of therapy. This raises the issue of whether 
non-aeruginosa Isolates of Pseudomonas  require specific antimicrobial therapy, In our study, 
Pseudomonas  cepacia  was not always regarded as a nonpathogenic organism as two patients 
with aztreonam-resistant Pseudomonas  cepacia  isolates in their sputum cultures were 
dropped from the study, although their Pseudomonas  aeruginosa  isolates were sensitive to 
aztreonam. However, as stated above, in spite of other resistant organisms most patients did well 
both clinically and microblologically, Recent reports have suggested that Pseudomonas  cepacia 
is Indeed a pathogenic organism, and colonization with this organism has been associated with the 
rapid deterioration and death of some cystic fibrosis patients who previously had relatively mild 
disease. 2 5 ' 2 6 It is interesting to note that Pseudomonas  cepacia  is rarely pathogenic in other 
patient populations,26 although It is widely distributed in nature. The question of whether non-
aeruginosa Pseudomonas  infections require specific therapy cannot easily be answered. Our 
data suggest that in  vitro  sensitivity of Pseudomonas  cepacia  and other non-aeruginosa 
Pseudomonas  Isolates to the antimicrobial therapy being used may not be related to clinical 
improvement. However, this issue and the issue of whether or not to treat patients with 
antipseudomonal agents at all are only two of many problems facing the clinician who treats cystic 
fibrosis patients. Whether or not there is 3 benefit of Pseudomonas  -specific drug therapy 
independent of other therapeutic measures is the older and perhaps more pressing question, 
Clearly, these and other issues will require further research. 
Conclusions 
Pulmonary complications from cystic fibrosis continue to be the major cause of morbidity 
and mortality, as well as expense, for afflicted patients. In this study, therapy with aztreonam 
caused a significant decrease in bacterial cell counts, with eradication in some cases, and resulted 
in clinical improvement during therapy. This improvement was sustained, though only partially, 
for at least seven days after therapy was stopped. In this study, patients were followed only for a 
maximum of 14 days posttherapy. The question of whether aztreonam results in longer periods 
without rehospitalization than other antibiotic regimens is not answered by these data. Emergence 
of resistance was not commonly found in this study. Aztreonam appears to have significant 
promise as an antipseudomonal agent for the treatment of Pseudomonas  pneumonia in cystic 
fibrosis patients, but requires further study in this population. A controlled trial comparing 
aztreonam to other B-lactam antibiotics would provide additional information as to the position 
that aztreonam should occupy in the treatment of these infections. 
The important issue of whether aztreonam would be cost effective in this setting over 
conventional therapy cannot be addressed at this time due to aztreonam not having received FDA 
approval for sale in the United States, and therefore its cost has yet to be established. FDA 
approval is expected shortly, however, and this is another issue that merits study. 
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TABLE 1. Patient demographics. 
Patient Initials Age (yrs) Sex Weight (kg) Previous pneumonias 
1 BA 6 M 1 7 . 0 10 8 
2 * RS 15 F 50,0 4 5 
3 J B 16 h 34.0 2 7 
4 YB 20 F 39.4 2 9 
5 KP 11 M 25.2 6 12 
6 RC M F 39.6 1 10 
7 PC 9 M 2 0 . 7 10 15 
8 RP 22 M •44.5 10 15 
9 R J 6 M 16.2 2 7 
10 LM 14 F 36.5 6 14 
1 1 BF 13 M 46.8 4 14 
12 KS 10 F 23.0 unknown 14 
13 LG 20 F 4 4 . 4 15 9 
14 FH 21 h 5 6 . 7 "many" 19 
15 CS 16 M 30.0 "several" 16 
16 J N 9 F 20.0 4 10 
1 7 KM 8 F 25.0 1 14 
18 SK 10 F 25.0 3 10 
19 TK 12 M •40,2 1 10 
2 0 * KP 15 M 39.2 6 5 
21 AM 6 F 18.4 1 11 
22 CM 10 M 28.3 0 11 
23 RM 16 M 40,1 3 11 
24 ND 14 F 38.6 2 14 
25 EA 32 M 62.4 >40 17 
•dropped due to isolation of resistant pathogenic organisms 
2 1 
T A B L E 2. Data from 20 evaluable patients ( A i l values are means±S.D.). 
WBC counts Pulmonary scores Clinical scores Colony counts 
( x 1000) ( l o g 1 0 CFU/ml 
E n t r y 10.5±3.3 6 . 3 ± 2 . 5 14.6±3.0 4 ,4±3.9 
D a y S 8.6±2.6 10,1 ±2.4 2 . 7 i 2 . 4 
Day 7 2.5±2,1 
End 7 , 4 ± 1,8 7 . 7 ± 1 . 7 1 .2±2.3 
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Partial clinical response 
Microbiological cure with reinfection 
Day 5 End Follow up 
4 (day 7 ) 4 
15 11 9 
5.3 7.5 
4 - 9 
8 - e 
2 3 9 
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4 4 10 
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Pseudomonas  aeruginosa  (mucoid) 
Log] o CFU/ml 9 
MIC 8 
Response 
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m s EHfl Follow up 
1 (day 7 ) 3 
9 9 11 
7 . 4 6.2 
4 3 8 
64 32 16 
4 3 8 
16 0,5 16 
4 - 2 
16 - 8 
4 - 3 






MIC ( u g / m l ) 
Pseudomonas 
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Logio C F U / m l 
MIC ( u g / m l ) 
Partial clinical response 
Microbiological cure 
E M I E N T 4 
Entry. m FOllOW UP, 
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Response 
Partial clinical response 
Microbiological cure 
PATIENT 
EDJJ F0110W UP 
Pulmonary status 
score 5 2 (day 7 ) 0 
Clinical score 15 11 7 7 
W B C ( x l O C O ) 9.2 1 0 . 7 7 . 3 
Microorganisms isolated 
Pseudomonas  aeruginosa  (mucoid) 
Log j o CFU/ml 7 no sputum no sputum no sputum 
MIC (ng/ml) 16 
Pseudomonas  aeruginosa 
Log j o CFU/ml 6 
MIC Cuo/ml) 32 
Response 
Partial clinical response 
Microbiological cure 
PATIENT 
EDlQi m s . End FOllQW, Up 
Pulmonary status 
score 6 0 (day 7 ) 3 
Clinical score 15 7 7 8 
W B C ( x l O O O ) 14.2 9.6 not done 
Microorganisms isolated 
Pseudomonas  aeruginosa 
Log i o CFU/ml 9 
MIC (pg/ml) 0.2 
- not done -
Pseudomonas  aeruginosa 
L o g ] 0 C F U / m l 10 




Enlerobacter  agglomerans 
Logi q CFU/ml 
MIC ( y g / m l ) 
3 
0 . 1 2 5 
» 
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Escherichia  coli 





Partial clinical response 
Microbiological cure with reinfection 
PATIENT 
Entry pay 5 
Pulmonary status 
score 9 3 (day 7 ) 
Clinical score 16 1 1 






MIC (ug/ml) 0 ,125 0 . 1 2 5 
Pseudomonas 
Log i o CFU/ml 
aeruginosa 
1 
MIC (ug/ml) 16 -
Pseudomonas 
Log io CFU/ml 
aeruginosa 
3 
MIC (ug/ml) 0 ,125 -
Pseudomonas 
Log] o CFU/ml 
aeruginosa 
MIC (ug/ml) - -
Response 
Partial clinical response 







WBC ( x 1 0 0 0 ) 
Microorganisms isolated 
Pseudomonas  aeruginosa 
Log i o CFU/ml 9 
MIC (ug/ml) 8 
Pseudomonas  aeruginosa  (mucoid) 
Log j o CFU/ml 9 
MIC ( u g / m l ) 32 
Pseudomonas  aeruginosa 
Log i o CFU/ml 
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Log i o CFU/ml 
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Partial clinical response 
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P A T I E N T 9 
Entry Day 5 
Pulmonary status 
score 2 (day 7 ) 
Clinical score 12 8 
WBC ( x l O O O ) 10.2 7.2 
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Pseudomonas 
L o g i c CFU/ml 






Log j o CFU/ml 







Log i o CFU/ml 












Partial clinical response 
Microbiological response could not be assessed 
3 2 
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7 . 7 
Pseudomonas  aeruginosa  (mucoid) 
Log i o CFU/ml 10 
MIC (pg/ml) 8 
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urn. imi m FOllOW UP 
Pulmonary status 
score 4 2 (day 7 ) 2 
Clinical score 15 10 9 9 
WBC ( x l O O O ) 1 1 . 4 6.1 5,3 
U t o E L o a n i s m s isolated 
Pseudomonas  aeruginosa  (mucoid) 
Log, o CFU/ml 9 
MIC ( u g / m l ) 0.5 0 . 1 2 5 
: 8 0.5 
Pseudomonas  aeruginosa  (mucoid) 
Log^o CFU/ml 9 




Pseudomonas  , non-aeruginosa (exact species could not be identified) 
L o g i o CFU/ml 9 
MIC ( u g / m l ) 2 
Pseudomonas  , non-aeruginosa (exact species could not be identified) 
Log i o CFU/ml 9 8 
MIC ( u g / m l ) 128 1 2 8 
Pseudomonas  , non-aeruginosa (exact species could not be identified) 
Log] o CFU/ml 
MIC ( u g / m l ) 
Pseudomonas  cepacia 
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Partial clinical response 
Microbiological cure with relapse 
9 
64 
0 , 1 2 5 
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Clinical score 13 9 8 8 
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Clinical score 13 
W B C ( x l O O O ) not done 
Microorganisms isolated 
Pseudomonas  aeruginosa  (mucoid) 
L o g i o CFU/ml 8 
MIC ( u g / m l ) 4 
Pseudomonas  aeruginosa 
L o g i o CFU/ml 9 
MIC ( u g / m l ) 4 
PATIENT 3 
2 (day 7 ) 
10 








Partial clinical response 
Microbiological failure 
PATIENT 
Entry Days End FOllOW UC 
Pulmonary status 
score 9 4 (day 7 ) 4 
Clinical score 18 14 10 10 
WBC ( x 1000) 16.8 12.4 13.5 
Minronrganisms isolated 
Pseudomonas 
Log i o CFU/ml 



















Log] o CFU/ml 
MIC (ug/mi) 
aeruginosa  (mucoid) 
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0 , 5 
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Partial clinical response 
Microbiological failure 
P A T I E N T 1 5 
Entry p a y s EDO follow up. 
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Clinical score 14 10 6 7 
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Clinical score 13 
W B C ( x l O O O ) 14.8 
Microorganisms isolated 
Pseudomonas  aeruginosa  {mucoid) 
L o g i o C F U / m l 3 
MIC (ug/ml) 0.5 
3 9 
PATIENT 1 
dsolS End follow up 
3 (day 7 ) 6 
8 6 12 
6.8 not done 
3 - 6 
0 . 2 5 - 8 
Clinical cure 




score 4 0 ( d a y 7 ) 
Clinical score 10 9 
W B C ( x l O O O ) 7 6 . 7 
Microorganisms isolated 
Pseudomonas  aeruginosa 
Log] o CFU/ml 10 
MIC ( u g / m l ) 0.5 
Pseudomonas  aeruginosa 
Log 10 CFU/ml 
MIC ( u g / m l ) 
Response 
Clinical cure 




Clinical score 16 
W B C ( x l O O O ) 9.8 
Microorganisms isolated 
Pseudomonas 
L o g i o CFU/ml 
MIC (ug/ml) 










Log i o CFU/ml 
MiC (ug/ml) 




Partial clinical response 
Microbiological cure with relapse 
PATIENT 18 
fifcS End Follow yp 
2 (day 7 ) 2 
9 7 9 
8 7 . 2 
5 not done 7 
8 " 4 
7 
0.125 
5 " 7 
1 " 0.25 
PATIENT 19 
M c y C a t s End Follow up 
Pulmonary status 
score 4 2 (day 7 ) 4 
Clinical score 12 8 6 8 
WBC ( x l O O O ) 8.2 7.4 8.4 
Microorganisms isolated 
Pseudomonas  aeruginosa 











Pseudomonas  aeruginosa  {mucoid) 
L o g i o CFU/ml 9 





Klebsiella  oxytoca 












PATIENT 2 0 
M c y Data £ M Follow,, up, 
Pulmonary status 
score 6 dropped dropped 
Clinical score 14 14 dropped 
WBC ( x l O O O ) 18 12.3 
Microorganisms isolated 
Pseudomonas  cepacia 
Log] o CFU/ml 8 6 " " 
MIC (ug/ml) 16 32 
Pseudomonas  cepacia 
Logj o CFU/ml 8 6 
MiC ( u g / m l ) 16 6 
Pseudomonas  aeruginosa 
L o g | 0 CFU/ml 6 - " 
MIC ( u g / m l ) 4 - " 
Pseudomonas  cepacia 
Loo 10 CFU/rnl 5 . . . . 
MIC ( u g / m l ) 0 . 1 2 5 
Haemophilus  influenzae 
Log i o CFU/ml 7 - " 
MiC (ug/ml) 0 . 1 2 5 
Response 
Clinical and microbiological responses were not assessed. The patient was dropped from the study 
on day 5. 
PATIENT 21 
Enicy Pay 5. 
Pulmonary status 
score 5 0 (day 7 ) 
Clinical score 13 8 
W B C ( x l O O O ) 6,9 6 . 4 
Microorganisms isolated 
Pseudomonas  aeruginosa 
Log i o CFU/ml 5 
MIC ( u g / m l ) 0.25 
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Clinical score 12 9 
W B C ( x l O O O ) 8.1 6 
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Response 
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Microbiological cure with relapse 
PATIENT 23 
^^^ ry Pay ^^  
Pulmonary status 
score 5 2 (day 7 ) 
Clinical score 11 11 
W B C ( x l O O O ) 9.9 8.1 
Microorganisms isolated 
Pseudomonas  aeruginosa 
Logj o CFU/ml 9 3 
MIC (pg/ml) 4 1 
Pseudomonas  aeruginosa 
Logj o CFU/ml 8 
MIC ( u g / m l ) 4 
Pseudomonas  aeruginosa  (m ucoid) 
Log i o CFU/ml - 3 
MIC ( u g / m l ) - 8 
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L o g i o CFU/ml " - 4 
MIC (ug/ml) - 1 
Response 
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W B C C x l O O O ) 6.8 
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Pseudomonas  aeruginosa  {mucoid) 
L o g i o C F U / m i 
MIC (ug/ml) 
Pseudomonas  aeruginosa 
Log i o CFU/ml 
MiC (ug/ml) 
Pseudomonas  aeruginosa 
Log] o CFU/ml 
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MIC (ug/ml) 
Klebsiella  oxytoca 
Log] o CFU/ml 6 
MIC (ug/ml) 0.031 
Pseudomonas  aeruginosa 
Log j o CFU/ml 8 
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i n i c y pay 5 
Pulmonary status 
score 4 2 (day 7 ) 
Clinical score 11 8 
WBC ( x 1 0 O O ) 1 2 , 7 not done 
Microorganisms isolated 
Pseudomonas  aeruginosa  (mucoid) 
log i o CFU /ml - 9 
MIC ( u g / m l ) - 0,5 
Pseudomonas  aeruginosa  (mucoid) 
LogiO CFU/ml 9 9 





A P P E N D I X B 
INFORMED CONSENT FORM 
The Efficacy of Aztreonam in Cystic Fibrosis 
Date: 
PURPOSE OF THE STUDY: 
The purpose of the research study in which you are being invited to participate is to evaluate the 
effectiveness of a new antibiotic, aztreonam, in the treatment of lung infections associated with 
cystic fibrosis, Aztreonam's effectiveness will be judged based on both clinical observations and 
laboratory tests. Ten to 15 patients will be involved in this study and all will receive aztreonam. 
DESCRIPTION OF PROCEDURES: 
Should you decide to participate in this study, you will receive aztreonam (instead of the usual 
antibiotics) for a normal course of therapy ( 8 to 14 days), Aztreonam will be given 
intravenously 4 times daily, You will receive physical examinations and blood, urine and sputum 
tests at the beginning of therapy, on day 7 , and after completing your course of therapy. The blood 
tests require about one and one-half teaspoonful of blood. If the bacteria growing in your sputum 
are not susceptible to aztreonam, your participation in the study will end and you will be treated 
with other, more appropriate antibiotics. 
If you are a female of child-bearing age, are sexually active and not using a reliable form of 
contraception you will be given a pregnancy test prior to your admission to this study. ( I f you are 
pregnant, breast feeding, or allergic to penicillin, you will not be allowed to participated this 
study.) 
As you will be required to return to the hospital for some post-therapy tests, we will pay you $50 
for completion of this phase of the study to make up for lost work, travel time, and inconvenience. 
R I S K S AND BENEFITS: 
The benefits of participating in this study include a more detailed and thorough evaluation of your 
disease and course of therapy and free treatment with a new antibiotic that may be equally or more 
effective than standard therapy, Risks of participating include those of venipuncture which may 
cause discomfort, redness, and a slight chance of Infection, and those of the study drug. Aztreonam 
may cause rash, itching, nausea, vomiting, diarrhea and phlebitis (redness and pain at the 
Injection site). It is also possible that aztreonam may be less effective than conventional therapy. 
A L T E R N A T I V E CARE: 
If you do not wish to participate in this study, you will receive normal care and treatment for your 
c u r r e n t infection, including the use of marketed antibiotics. Failure to participate will result in 
no prej udice to your current or future medical care. 
5 0 
CONFIDENTIALITY: 
All information gathered in this study will be held In strict confidence. While such Information 
will be used for medical ana scientific purposes including publication, your identity will not be 
revealed. Additionally, this information will be available for inspection by the sponsor (E.R. 
Squibb & Sons, Inc.) and the Food and Drug Administration. 
F U R T H E R INFORMATION; 
Should you have further questions during or after the study you may contact Dr. John Bossc ( 5 8 1 -
7 5 4 5 or 9 4 2 - 4 5 2 5 ) , Dr. Dwight Marble ( 5 8 1 - 3 9 7 4 ) , or Dr. Phil Black ( 5 8 1 - 2 4 1 0 ) . If 
problems arise that you do not wish to discuss with one of the investigators, you may contact the 
University's Institutional Review Board at 581 - 3 6 5 5 . 
L I A B I L I T Y ; 
In the event you sustain physical injury resulting from the research project in which you are 
participating, the University of Utah will provide you, without charge, emergency and temporary 
medical treatment not otherwise covered by insurance. Furthermore, if your injuries are caused 
by negligent acts or omissions of University employees acting in the course and scope of their 
employment, the University may be liable, subject to limitations prescribed by law, for additional 
medical costs and other damages you sustain. If you believe that you have suffered a physical 
I n j u r y as a result of participating in this research program, please contact the Office of Research 
Administration, telephone number 5 8 1 - 6 9 0 3 . 
V O L U N T A R Y PARTICIPATION; 
Y o u r participation in this stud/ is totally voluntary and you are free to withdraw at any time 
without prejudice to further medical care. 
C O N S E N T TO PARTICIPATE: 
I n signing below you agree to participate as a research subject In this stydy and acknowledge the 
fact that you have had a fair opportunity to ask questions about the above mentioned procedures. 
You w i l l be given a copy of this form. 
Patient Name; Signature; 
P a r e n t or Guardian Signature; : 
Investigator Signature: 
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